PDCD1 and neoplasm: Despite completely different targeting strategies, where CEA-IL-2v and FAP-IL-2v target tumors and PD1-IL-2v targets tumor-infiltrated T cells, these IL-2v fusion proteins showed comparable tolerability in humans, with maximal tolerated doses of approximately 0.3-0.5 mg/kg.